1. Humoral Response to mRNA versus an Adenovirus Vector-Based SARS-CoV-2 Vaccine in Dialysis Patients
- Author
-
Linda H. Ficociello, Ines A. Dahne-Steuber, Michael S. Anger, Ruchir Patel, Robert J. Kossmann, Amit Fadia, Josephine DeLisi, Jeffrey Hymes, Claudy Mullon, Melanie C. Pollan, Curtis Johnson, Joanna Willetts, Chance Mysayphonh, and Jeffrey G. Mulhern
- Subjects
Transplantation ,Messenger RNA ,biology ,Coronavirus disease 2019 (COVID-19) ,Epidemiology ,business.industry ,medicine.medical_treatment ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,Critical Care and Intensive Care Medicine ,Dialysis patients ,Viral vector ,Vaccination ,Nephrology ,Immunology ,Research Letter ,biology.protein ,Medicine ,Antibody ,business ,Dialysis - Abstract
Patients on maintenance dialysis may be immunocompromised and have comorbidities that modulate the response to coronavirus disease 2019 (COVID-19) vaccines. We conducted a quality improvement project to characterize the antibody response to COVID-19 vaccination in two dialysis clinics in Arizona
- Published
- 2021